Solubility, Crystallization, and Characterization of Cytidine Sulfate.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
18 Jul 2023
18 Jul 2023
Historique:
received:
13
04
2023
accepted:
10
05
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Cytidine is an important kind of nucleoside that can be applied to drug development and food industry. Cytidine sulfate is one of its popular forms, which is promising as a medicinal intermediate, especially in antiviral and antitumor drugs. Product refining is the key point of industrial development, and crystallization is a significant way of refining. In this work, the solubility of cytidine sulfate in pure water from 278.15 to 328.15 K and in water-ethanol binary solvents at 298.15 K was measured by the UV spectroscopic method. The solubility data were correlated with temperature and solvent composition using the modified Apelblat, van't Hoff, and CNIBS/R-K equations. On this basis, we investigated and compared three crystallization processes, and the coupling method was developed to prepare crystals with a large particle size, concentrated distribution, and high yield and packing density. In addition, the structure and stability of the products were characterized by powder X-ray diffraction, Fourier transform infrared spectroscopy, thermogravimetric analysis, differential scanning calorimetry, and dynamic vapor sorption analysis. It was found that cytidine sulfate has only one crystal form in our research process, and the product of coupling crystallization is stable and favorable for industrial development.
Identifiants
pubmed: 37483214
doi: 10.1021/acsomega.3c02501
pmc: PMC10357447
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25288-25294Informations de copyright
© 2023 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Eur J Pharm Sci. 2003 Aug;19(5):423-32
pubmed: 12907293
Int J Pharm. 2006 Sep 14;321(1-2):101-7
pubmed: 16784825
Biotechnol Adv. 2015 Sep-Oct;33(5):412-34
pubmed: 25795057
Curr Med Chem Anticancer Agents. 2003 Jul;3(4):263-70
pubmed: 12769772
Cancer Res. 1991 Jan 15;51(2):741-3
pubmed: 1985792
Int J Antimicrob Agents. 2009 Apr;33(4):307-20
pubmed: 19108994
Eur J Pharm Sci. 2008 Mar 3;33(3):230-40
pubmed: 18207706
Drug Discov Today. 2003 Oct 1;8(19):898-905
pubmed: 14554018
Eur J Pharm Biopharm. 2004 Mar;57(2):411-20
pubmed: 15019002
Org Process Res Dev. 2021 Dec 17;25(12):2679-2685
pubmed: 34955627